祥生医疗(688358) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 was RMB 46,876.66 million, a decrease of 3.12% compared to the previous year[4] - Net profit attributable to shareholders was RMB 14,335.72 million, down 2.13% year-on-year[4] - Net profit excluding non-recurring gains and losses was RMB 12,997.49 million, a decline of 5.28% from the previous year[4] - Basic earnings per share decreased to RMB 1.28, down 3.76% compared to the same period last year[4] - The weighted average return on equity decreased by 0.63 percentage points to 10.32%[4] Assets and Equity - Total assets at the end of the reporting period were RMB 159,971.45 million, an increase of 5.07% year-on-year[4] - Shareholders' equity attributable to the parent company rose to RMB 142,326.34 million, up 3.96% from the previous year[4] - The net asset value per share attributable to shareholders increased to RMB 12.69, a growth of 3.93% year-on-year[4] Strategic Initiatives - The company's strategy includes increasing R&D investment and accelerating the market introduction of new products[7] - The company is enhancing its marketing team and optimizing its marketing structure to meet future market demands[7]